Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts
Archives of Toxicology · 2023-02 · 97 (2) · 377-392
DOI: 10.1007/s00204-022-03418-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Toxicology, online erschienen am 23.11.2022. Verfasst von Chun-Ying Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 21000…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neuroblastoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Specially Appointed Medical Expert Project of Jiangsu Commission of Health, Scientific Research Foundation for Returned Scholars of Ministry of Education.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Vincristine (VCR), an effective antitumor drug, has been utilized in several polytherapy regimens for acute lymphoblastic leukemia, neuroblastoma and rhabdomyosarcoma. However, clinical evidence shows that the metabolism of VCR varies greatly among patients. The traditional based body surface area (BSA) administration method is prone to insufficient exposure to VCR or severe VCR-induced peripheral neurotoxicity (VIPN). Therefore, reliable strategies are urgently needed to improve efficacy and reduce VIPN. Due to the unpredictable pharmacokinetic changes of VCR, therapeutic drug monitoring (TDM) may help to ensure its efficacy and to manage VIPN. At present, there is a lot of supporting evidence for the suitability of applying TDM to VCR therapy. Based on the consensus guidelines drafted by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), this review aimed to summarize various available data to evaluate the potential utility of VCR TDM for cancer patients. Of note, valuable evidence has accumulated on pharmacokinetics variability, pharmacodynamics, drug exposure-clinical response relationship, biomarkers for VIPN prediction, and assays for VCR monitoring. However, there are still many relevant clinical pharmacological questions that cannot yet be answered merely based on insufficient evidence. Currently, we cannot recommend a therapeutic exposure range and cannot yet provide a dose-adaptation strategy for clinicians and patients. In areas where the evidence is not yet sufficient, more research is needed in the future. The precision medicine of VCR cannot rely on TDM alone and needs to consider the clinical, environmental, genetic background and patient-specific factors as a whole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210008, China.
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
- Department of Solid Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
- Department of Hematology /Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
- Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210008, China. huyahui324@163.com.
Förderung
- National Natural Science Foundation of China
- Specially Appointed Medical Expert Project of Jiangsu Commission of Health
- Scientific Research Foundation for Returned Scholars of Ministry of Education
Zitieren
APA
Wu, C. Y., Li, G. T., Chu, C. C., Guo, H. L., Fang, W. R., Li, T., Wang, Y. R., Xu, J., Hu, Y. H., Zhou, L., & Chen, F. (2023). Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts. Archives of Toxicology, 97(2), 377-392. https://doi.org/10.1007/s00204-022-03418-8
Vancouver
Wu CY, Li GT, Chu CC, Guo HL, Fang WR, Li T, et al. Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts. Archives of Toxicology. 2023;97(2):377-392. doi:10.1007/s00204-022-03418-8
BibTeX
@article{Wu2023,
author = {Wu, Chun-Ying and Li, Guan-Ting and Chu, Chen-Chao and Guo, Hong-Li and Fang, Wei-Rong and Li, Tao and Wang, Yong-Ren and Xu, Jing and Hu, Ya-Hui and Zhou, Li and Chen, Feng},
title = {Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts},
journal = {Archives of Toxicology},
year = {2023},
volume = {97},
number = {2},
pages = {377--392},
doi = {10.1007/s00204-022-03418-8}
}
EUVIMED